Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!
you are here: HomeNewsIndia

Global growth to be hit if IP norms not waived to deal with COVID-19: India

In October 2020, India and South Africa submitted a proposal suggesting a waiver for all WTO (World Trade Organization) members on the implementation, application and enforcement of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19.

February 28, 2021 / 08:34 AM IST

India said if members of the WTO would fail to deliver on a proposal on waiving certain intellectual property obligations to deal with COVID-19 pandemic, it would impact global growth and livelihood.

In October 2020, India and South Africa submitted a proposal suggesting a waiver for all WTO (World Trade Organization) members on the implementation, application and enforcement of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19.

The agreement on Trade-Related Aspects of Intellectual Property Rights or TRIPS came into effect in January 1995. It is a multilateral agreement on intellectual property (IP) rights such as copyright, industrial designs, patents and protection of undisclosed information or trade secrets.

"If we fail in the next one or two quarters or not delivering on that, let me tell you that it is not the question of equity, we are coming in the way of global growth and livelihood. It is not that we are coming in the way of life.

"It is a very simple economics that for a commercial interest of let us say USD 30 to USD 40 billion of annual vaccine output of few companies, we are coming in the way of USD 6-7 trillion of global GDP output in one year," Indian Ambassador and Permanent Representative to the WTO, Brajendra Navnit, said at the Asia Economic Dialogue.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Developed and rich nations are opposing the proposal. Commerce and Industry Minister Piyush Goyal had recently stated that on one hand, the developed countries talk about supporting each other and multilateral fight against COVID-19 pandemic, but on the other hand, they are looking at protecting the interests of a few companies.

The minister has added that the world is fighting the pandemic which could potentially cost USD 9 trillion to the world economy. Further, Navnit said that it does not make any sense that on one side countries are providing USD 1 trillion or USD 1.5 trillion worth of fiscal stimulus, but on the other hand they are not willing to compensate for design a remuneration for IP rights' holder and expand the manufacturing by just putting USD 30-40 billion in bucket.

Speaking at the event, Xolelwa Mlumbi-peter, Ambassador and Permanent Representative of South Africa to the WTO, said that IP should not become a barrier to access affordable medicines. Suggesting for holding frequent meetings of political leadership at WTO, the Ambassador said: "I strongly feel that diplomats and bureaucrats have taken over the system and they want to keep the political leadership slightly away".

He added that the general council of the WTO has totally taken over the mandate of MC (ministerial conference), which is the highest decision making body of the WTO. He added that members can go ahead and start having more frequent interactions with political leadership "because most of the calls have to be taken by them and it can not be settled by diplomats sitting in Geneva".

Geneva-based WTO deals with global trade and adjudicates trade disputes among member countries. Further, he added that the members should moderate their expectations from the 12th MC, expected later this year.

On special and differential treatment,  Aguiar Machado, Ambassador and Permanent Representative of EU to WTO, said that there is need to have a frank and open debate on the issue. "We cannot pretend that developing countries want to be integrated into the multilateral trading system while at the same time sitting at the margins of that system," he said.

Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

first published: Feb 28, 2021 08:35 am
ISO 27001 - BSI Assurance Mark